Clinical Trial Update: SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD [Phase 4]

View source ↗

Summary

Phase 4 trial comparing an SGLT2 inhibitor with a sulfonylurea in type 2 diabetes patients with non-alcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Kanazawa University | Conditions: Non-alcoholic Fatty Liver Disease | Phase 4 | Status: COMPLETED